News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study

(June 8, 2017) - Adamas Pharmaceuticals, Inc. presented an updated analysis of efficacy and tolerability data from EASE LID 2, the company’s ongoing Phase 3 open-label, long-term safety and efficacy study of ADS-5102 (amantadine) extended-release capsules. Overall, results demonstrated that ADS-5102 was well tolerated and the treatment effect on motor complications. The analyses were presented in a poster session at the 21st International Congress of Parkinson’s Disease and Movement Disorders in Vancouver, Canada. Read more